Peptide News Digest

#Peptides-Plus

1 story

Industry · View digest

CNBC: Hims & Hers Launches Peptides+ With Five Unapproved Compounded Treatments, Including Sermorelin and Glutathione

Hims & Hers launched Peptides+ on November 18 with compounded sermorelin, glutathione, NAD+, vitamin B12, and L-carnitine, none of them FDA-approved, CNBC reported. More than 10,000 people joined its early access list within 15 days, according to a company spokesperson, and Hims plans to add BPC-157 and TB-500 later without giving a date. Chief medical officer Dr. Anant Vinjamoori said, "We don't have all of this data that we're used to having with compounds like this." For now, patients with serious heart, liver, or kidney disease are not eligible.